BioNTech SE

BNTXNASDAQHealthcare● Active

$88.08

$-1.51(-1.69%)

Market Cap$22.3B

P/E Ratio—

52W High$124

52W Low$79.52

Avg Volume1.2M

Open$89.51

Beta1.32

Overview

BioNTech SE (BNTX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BNTX · free cash flow · updated Jun 8, 2026

Core FCF metrics

BNTX · FCF · TTM · margin & CAGR

Free cash flow was $269.8M for FY2025 (fiscal year ending 2025-12-31), up 210.3% year-over-year The FCF margin was 9.8%.

FY2025 Free Cash Flow$269.8M▲ +210.3% YoY

Trailing 12M (TTM)$1.26Btrailing 4 quarters sum

FCF Margin9.8%$269.8M ÷ revenue

3-Year CAGR-72.7%FY2022 → FY2025

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BNTX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$438.0M(168M)$269.8M▲ +210.3%9.8%

FY2024$207.7M(452M)−$244.6M▼ 105.2%-8.9%

FY2023$5.37B(706M)$4.67B▼ 64.7%122.2%

FY2022$13.58B(363M)$13.21B▲ +1696.1%76.3%

FY2021$889.7M(154M)$735.7M▲ +843.9%3.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BNTX · P/FCF · FCF yield · FCF per share

BioNTech SE (BNTX) trades at a FCF yield of 3.54% and a price-to-free-cash-flow ratio of 16.8x. FCF per share stands at $5.23, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

3.54%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$5.23

TTM FCF ÷ Shares Outstanding

Price / FCF

x16.8

Share Price ÷ FCF per Share

EV / FCF (TTM)

x14.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BNTX · cash flow statement · operating / investing / financing

For FY2025, BioNTech SE generated $438.0M in operating cash flow and spent 168M in capital expenditures, yielding $269.8M in free cash flow.

Operating Activities

+$438.0M

Cash from core business operations

2025-12-31

Investing Activities

−$2.37B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$50.8M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($438.0M) − |CapEx| (168M) = FCF ($269.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BNTX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

BioNTech SEYOU

BNTX

$269.8M+210.3%9.8%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

BioNTech SE (BNTX) reported free cash flow of $269.8M for FY2025 (fiscal year ending 2025-12-31), up 210.3% year-over-year. The FCF margin was 9.8%.

Based on available data, BioNTech SE has maintained positive free cash flow for at least 4 fiscal year(s). FCF peaked at $13.21B in FY2022.

BioNTech SE's FCF yield is 3.54% and price-to-FCF ratio is 16.8x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BNTX free cash flow · 8 questions

BioNTech SE free cash flow was $269.8M for FY2025, up 210.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $1.26B.

BNTX free cash flowBNTX FCFBNTX FCF 2025BNTX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · BioNTech SE · BioNTech SE SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026